Dr. Allen L. Cohn
Claim this profileRocky Mountain Cancer Centers
Studies Colorectal Cancer
Studies Tumors
18 reported clinical trials
36 drugs studied
About Allen L. Cohn
Education:
- Obtained MD from the University of Colorado School of Medicine in 1986.
- Completed Residency in Internal Medicine at the University of Colorado Health Sciences Center in 1989.
- Finished Fellowship in Hematology/Oncology at the University of Colorado Health Sciences Center in 1992.
Experience:
- Board-certified in Internal Medicine, Hematology, and Medical Oncology.
- Associated with Rocky Mountain Cancer Centers.
Area of expertise
1Colorectal Cancer
Stage IV
Stage III
HER2 positive
2Tumors
Stage IV
Stage III
PD-L1 positive
Affiliated Hospitals
Clinical Trials Allen L. Cohn is currently running
Tucatinib + Trastuzumab + Chemotherapy
for Colorectal Cancer
This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease. Participants in this study have colorectal cancer that has spread through the body (metastatic) and/or cannot be removed with surgery (unresectable). Participants will be assigned randomly to the tucatinib group or standard of care group. The tucatinib group will get tucatinib, trastuzumab, and mFOLFOX6. The standard of care group will get either: * mFOLFOX6 alone, * mFOLFOX6 with bevacizumab, or * mFOLFOX6 with cetuximab mFOLFOX6 is a combination of multiple drugs. All of the drugs given in this study are used to treat this type of cancer.
Recruiting2 awards Phase 3
Futibatinib + PD-1 Antibody
for Esophageal Cancer
This is a nonrandomized, uncontrolled, open-label, multicenter Phase 2 study to evaluate the efficacy, safety, and tolerability of futibatinib in combination with PD-1 antibody-based SoC therapy in adult patients with solid tumors.
Recruiting1 award Phase 2
More about Allen L. Cohn
Clinical Trial Related1 year of experience running clinical trials · Led 18 trials as a Principal Investigator · 9 Active Clinical TrialsTreatments Allen L. Cohn has experience with
- Nivolumab
- Ipilimumab
- Fluorouracil
- Oxaliplatin
- Cetuximab
- Bevacizumab
Breakdown of trials Allen L. Cohn has run
Colorectal Cancer
Prostate Cancer
Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Allen L. Cohn specialize in?
Allen L. Cohn focuses on Colorectal Cancer and Tumors. In particular, much of their work with Colorectal Cancer has involved Stage IV patients, or patients who are Stage III.
Is Allen L. Cohn currently recruiting for clinical trials?
Yes, Allen L. Cohn is currently recruiting for 9 clinical trials in Lakewood Colorado. If you're interested in participating, you should apply.
Are there any treatments that Allen L. Cohn has studied deeply?
Yes, Allen L. Cohn has studied treatments such as Nivolumab, Ipilimumab, Fluorouracil.
What is the best way to schedule an appointment with Allen L. Cohn?
Apply for one of the trials that Allen L. Cohn is conducting.
What is the office address of Allen L. Cohn?
The office of Allen L. Cohn is located at: Rocky Mountain Cancer Centers, Lakewood, Colorado 80228 United States. This is the address for their practice at the Rocky Mountain Cancer Centers.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.